BioRem Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was CAD 12.96 million compared to CAD 17.95 million a year ago. Net loss was CAD 0.147123 million compared to net income of CAD 0.825199 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to basic earnings per share from continuing operations of CAD 0.05 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to diluted earnings per share from continuing operations of CAD 0.04 a year ago.